 |
|
Synthetic Cannabinoid May Aid Fertility in Smokers
December 04, 2006BUFFALO, N.Y. - A reproductive medicine specialist at the University at Buffalo has shown that a new compound may improve the fertility of tobacco smokers who have low sperm count and low percentage sperm motility.
The sperm from male smokers were washed with a synthetic chemical called AM-1346. After incubation, there was a doubling in the fertilizing capacity of sperm from poor quality semen, results showed.
Lani Burkman, Ph.D., and colleagues presented the findings at the 2006 meeting of the American Society of Reproductive Medicine held recently in New Orleans.
"Based on our previous data and published literature, it is clear that most tobacco smokers will exhibit a small or a significant decline in fertility," she stated. "Nicotine addiction is quite powerful. The best solution is to stop smoking and then wean yourself off of all nicotine products. But for smokers who can't quit, the in vitro use of AM-1346 may significantly improve their fertilizing capacity."
Burkman, associate professor in the departments of gynecology/obstetrics and urology and head of the Section on Andrology in the UB School of Medicine and Biomedical Sciences, previously demonstrated that sperm functions critical for fertilization are altered by nicotine exposure, whether in vitro, or through long-term tobacco use. Two-thirds of the male smokers studied had decreased fertility; some showed a serious loss.
The new study involved nine selected smokers (22 experiments) who had been evaluated previously for sperm fertilizing potential using the outside cover of a human egg, called the zona pellucida. Four men had a high number of sperm attaching to the zona (normal, Group I), while five other smokers had sperm with poor egg binding (poor fertilizing potential, Group II).
The new experiments were designed to evaluate whether sperm with poor fertilizing capacity from smokers could be treated so that egg binding was improved. Specifically, the researchers studied a potential interaction between two chemical systems that control sperm.
"Human sperm carry the cholinergic receptor, which responds to the neurotransmitter acetylcholine," noted Burkman. "Nicotine mimics acetylcholine and binds to the cholinergic receptor." In earlier research, Burkman and colleagues also showed that human sperm contain cannabinoid receptors, which respond to marijuana, as well as natural cannabinoids occurring in the body.
"Research from other scientists indicates that the cholinergic system and the cannabinoid system naturally regulate human sperm and help prepare them for fertilizing an egg," she said. "Our research suggests that this natural regulation is out of balance for the majority of smokers when sperm are continuously exposed to nicotine.
"We think there is an important communication between the cannabinoid and cholinergic receptor systems in human sperm," said Burkman. "No one has shown this interaction before when looking at human tissue. AM-1346, the drug that we tested, is a synthetic version of a natural cannabinoid found in the body.
"In 22 Hemizona tests, we showed that the response to AM-1346 depended on the initial fertility of the tobacco smoker, and if his semen showed poor quality, meaning low sperm count and low percentage motility."
The sperm from Group II volunteers were incubated with AM-1346 for several hours and then retested in the Hemizona Assay. Six experiments in Group II started with semen of low quality and all six resulted in stimulation of sperm binding to the zona ranging from 133 percent to 330 percent, with a mean of 201 percent, when compared to their own untreated sperm, results showed.
"In contrast," said Burkman, "samples from Group I (normal fertility, normal semen quality) reacted in the opposite manner. This two-way, or biphasic, response is common for cannabinoid action. With Group I, the drug AM-1346 caused a substantial decrease in sperm binding to the zona for eight out of nine samples.
"This opposite response must be studied further," Burkman said. "It might be tied to early-versus-late steps in fertilization, where it is expected that one process is slowed down while another process is stimulated.
"It does appear that sperm functioning in tobacco smokers with low fertility and low semen quality is quite different when compared to smokers with higher fertility and good semen quality. Nicotine appears to change the sperm membranes and sperm receptors. It also raises the question of why sperm from some smokers are protected from the effects of tobacco and nicotine."
Roxanne Mroz and MaryLou Bodziak, UB research associates, contributed to this work, along with UB undergraduate students Stuti Tambar and Brian Telesz. Alexandros Makriyannis, Ph.D., from Northeastern University, created AM-1346.
The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York. The School of Medicine and Biomedical Sciences is one of five schools that constitute UB's Academic Health Center.
The University at Buffalo
"Based on our previous data and published literature, it is clear that most tobacco smokers will exhibit a small or a significant decline in fertility," she stated. "Nicotine addiction is quite powerful. The best solution is to stop smoking and then wean yourself off of all nicotine products. But for smokers who can't quit, the in vitro use of AM-1346 may significantly improve their fertilizing capacity."
Burkman, associate professor in the departments of gynecology/obstetrics and urology and head of the Section on Andrology in the UB School of Medicine and Biomedical Sciences, previously demonstrated that sperm functions critical for fertilization are altered by nicotine exposure, whether in vitro, or through long-term tobacco use. Two-thirds of the male smokers studied had decreased fertility; some showed a serious loss.
The new study involved nine selected smokers (22 experiments) who had been evaluated previously for sperm fertilizing potential using the outside cover of a human egg, called the zona pellucida. Four men had a high number of sperm attaching to the zona (normal, Group I), while five other smokers had sperm with poor egg binding (poor fertilizing potential, Group II).
The new experiments were designed to evaluate whether sperm with poor fertilizing capacity from smokers could be treated so that egg binding was improved. Specifically, the researchers studied a potential interaction between two chemical systems that control sperm.
"Human sperm carry the cholinergic receptor, which responds to the neurotransmitter acetylcholine," noted Burkman. "Nicotine mimics acetylcholine and binds to the cholinergic receptor." In earlier research, Burkman and colleagues also showed that human sperm contain cannabinoid receptors, which respond to marijuana, as well as natural cannabinoids occurring in the body.
"Research from other scientists indicates that the cholinergic system and the cannabinoid system naturally regulate human sperm and help prepare them for fertilizing an egg," she said. "Our research suggests that this natural regulation is out of balance for the majority of smokers when sperm are continuously exposed to nicotine.
"We think there is an important communication between the cannabinoid and cholinergic receptor systems in human sperm," said Burkman. "No one has shown this interaction before when looking at human tissue. AM-1346, the drug that we tested, is a synthetic version of a natural cannabinoid found in the body.
"In 22 Hemizona tests, we showed that the response to AM-1346 depended on the initial fertility of the tobacco smoker, and if his semen showed poor quality, meaning low sperm count and low percentage motility."
The sperm from Group II volunteers were incubated with AM-1346 for several hours and then retested in the Hemizona Assay. Six experiments in Group II started with semen of low quality and all six resulted in stimulation of sperm binding to the zona ranging from 133 percent to 330 percent, with a mean of 201 percent, when compared to their own untreated sperm, results showed.
"In contrast," said Burkman, "samples from Group I (normal fertility, normal semen quality) reacted in the opposite manner. This two-way, or biphasic, response is common for cannabinoid action. With Group I, the drug AM-1346 caused a substantial decrease in sperm binding to the zona for eight out of nine samples.
"This opposite response must be studied further," Burkman said. "It might be tied to early-versus-late steps in fertilization, where it is expected that one process is slowed down while another process is stimulated.
"It does appear that sperm functioning in tobacco smokers with low fertility and low semen quality is quite different when compared to smokers with higher fertility and good semen quality. Nicotine appears to change the sperm membranes and sperm receptors. It also raises the question of why sperm from some smokers are protected from the effects of tobacco and nicotine."
Roxanne Mroz and MaryLou Bodziak, UB research associates, contributed to this work, along with UB undergraduate students Stuti Tambar and Brian Telesz. Alexandros Makriyannis, Ph.D., from Northeastern University, created AM-1346.
The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York. The School of Medicine and Biomedical Sciences is one of five schools that constitute UB's Academic Health Center.
The University at Buffalo
Cannabinoid Current Events and Cannabinoid News RSSImpact of cannabis on bones changes with age, study finds
Scientists investigating the effects of cannabis on bone health have found that its impact varies dramatically with age.
Marijuana use linked to increased risk of testicular cancer
Frequent and/or long-term marijuana use may significantly increase a man's risk of developing the most aggressive type of testicular cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center. The study results were published online Feb. 9 in the journal Cancer.
Scripps research team defines new painkilling chemical pathway
Marijuana kills pain by activating a set of proteins known as cannabinoid receptors, which can also regulate appetite, inflammation, and memory.
New cannabis-like drugs could block pain without affecting brain, says study
A new type of drug could alleviate pain in a similar way to cannabis without affecting the brain, according to a new study published in the journal Pain on Monday 15 September.
Milestone for cannabinoid MS study
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Opioids and cannabinoids influence mobility of spermatozoids
A PhD thesis from the University of the Basque Country has concluded that there are opioid and cannabinoid receptors in human sperm and that these influence the mobility of spermatozoid.
Medicines derived from cannabis: a review of adverse events
Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.
New Mount Sinai research tracks effects of addictive drugs on brain
Mount Sinai researchers may have unlocked the key to better understanding the effect addictive drugs have on the human brain.
U of Minnesota researcher discovers the starting point of sun-induced skin cancer
According to a new study from the University of Minnesota, the earliest event in the development of sun-induced skin cancer may have been identified.
More Cannabinoid Current Events and Cannabinoid News Articles
 |
Cannabinoids (Handbook of Experimental Pharmacology) (Volume 168) by Roger G. Pertwee (Editor) The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions. |
 |
Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Ethan B Russo (Author) Presents an objective and comprehensive description of the state of the art of medicinal cannabis. Contains new and updated data based on international sources. Hardcover, softcover also available. |
 |
Medicinal Uses of Cannabis and Cannabinoids by Geoffrey W. Guy (Editor), Brian A. Whittle (Editor), Philip J. Robson (Editor) In recent years, cannabis research has moved beyond its use as an illegal recreational drug to consider its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis. Although there is a considerable body of primary literature relating to the medicinal use of cannabis, much of the published work concerns anecdotal reports. This title describes all the contemporary research findings relating to the medicinal use of cannabis and cannabinoids, and reports on the pharmacology, formulation, safety and efficacy of cannabis as a therapeutic agent. This should be a useful reference for pharmacists, doctors, pharmacologists and all other healthcare professionals with an interest in pain control. |
 |
Cannabinoids and the Brain by Attila Köfalvi (Author), Attila Köfalvi (Editor) Endocannabinoids control most of the body functions, and in the brain, they modulate neurotransmission, synaptic plasticity, confer neuroprotection, control metabolism, neuro- and neuritogenesis, survival, cognitive and motor functions as well as a plethora of other higher-order brain functions. Their fruitful therapeutic potential is recognized by cannabinoid researchers and pharmaceutical companies, respectively. The aim of this book is to help clinicians, neuroscientists, as well as students, understand the significance of the endocannabinoid system. This book, however, also will be very useful to those who already feel comfortable with the neuroscience of endocannabinoids. The book will introduce the reader to the up-to-date neurobiology of endocannabinoids and related... |
 |
Cannabinoids as Therapeutics (Milestones in Drug Therapy) by Raphael Mechoulam (Editor) In recent years, cannabis research has concentrated on the potential of cannabinoids as therapeutic substances, particularly in serious chronic illnesses such as multiple sclerosis. Most volumes published on cannabinoids so far concentrate on the biological activity, biochemistry and pharmacology, whereas this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research. |
 |
Cannabinoids in Nature and Medicine by Didier M. Lambert (Editor) Originally a special issue of Chemistry & Biodiversity, the first part of this volume focuses on the plant Cannabis sativa, its active ingredients, and the discovery of cannabinoid receptors as well as the therapeutic applications of activating, or blocking, the receptors. Following an overview of the plant, its medicinal uses, and its preparations, further chapters cover biosynthetic pathways, pharmacological properties, cannabis-based medicine, toxicology, cannabis prohibition and clinical situations where blocking the cannabinoid receptors might be beneficial. The second part covers the journey from humans to plants, analyzing anandamide, as well as other endocannabinoids and endocannabinoid congeners, biosynthetic pathways, current knowledge of FAAH-1, FAAH-2, monoglyceride... |
 |
The Cannabinoid Receptors (The Receptors) by Patricia H. Reggio (Editor) As research has progressed, the cannabinoid CB 1 and CB 2 receptors have expanded significantly in importance within the neuroscience mainstream. In The Cannabinoid Receptors, leading experts introduce newcomers to the cannabinoid field with chapters covering cannabinoid ligand synthesis and structure activity relationships, the molecular pharmacology of the cannabinoid receptors and the endocannabinoid system, and ultimately, the whole animal pharmacology and therapeutic applications for cannabinoid drugs. Adding to those key topics, the book also examines the current direction of the field with chapters on new putative cannabinoid receptors and challenges for future research. As a part of The Receptors ™ series, this volume highlights its receptor with the most thorough, focused... |
 |
Marijuana and the Cannabinoids (Forensic Science and Medicine) by Mahmoud A. ElSohly (Editor) Marijuana and the Cannabinoids presents a compendium of research into the botany, chemistry, and pharmacology of cannabis and the medicinal aspects of the cannabinoids. While medicinal use of Cannabis sativa L. has been reported for over 5000 years, interest in its medicinal potential and controversy surrounding its illicit use have grown exponentially since the identification of the chemical structure of the plant's active constituent (D9-THC) in 1964. This volume presents the findings of researchers on the forefront of this emerging and controversial field of study. Chapter 1 is an overview of Cannabis and natural Cannabis medicines, while Chapter 2 focuses on the chemistry and analysis of phytocannabinoids and other Cannabis constituents. Chapter 3 discusses the potential of chemical... |
 |
Marijuana and Cannabinoid Research: Methods and Protocols (Methods in Molecular Medicine) by Emmanuel S. Onaivi (Editor) A cutting-edge collection of readily reproducible in vitro and in vivo methods to elucidate the mechanisms associated with cannabinoid function in health and disease. The techniques can be used in studies across the board from genes to behavior. The molecular neurobiological methods are invaluable in analyzing the structure, the polymorphisms, and the molecular expression of the cannabinoid receptors (CBrs), as well as their association with polysubstance abuse. There are also methods for localizing cannabinoid receptors in different systems, visualizing cannabinoid effects using brain slice imaging and elctrophysiological approaches, and designing and synthesizing cannabinoids and endocannabinoids. The protocols follow the successful Methods in Molecular Medicine™ series format, each... |
 |
Cannabinoids (Neuroscience Intelligence Unit) by Vincenzo Di Marzo (Editor) The 21st century will witness the unprecedented marketing of therapeutic drugs developed from cannabinoids and the endocannabinoid system. Cannabinoids is a timely volume, which represents a comprehensive review of the most important issues in cannabinoid research as well as those of most likely therapeutic relevance. For the first time, the multi-faceted aspects of cannabinoid chemistry, biology and medicine are presented in one volume. Key topics of discussion: major families of phytocannabinoids; pharmacological activity of phytocannabinoids; interactions of phytocannabinoids with their proposed molecular target; components of the endocannabinoid system; molecular mechanisms of the endocannabinoid system; Physiological and pathological role of endocannabinoids; industrial... |
| © 2009 BrightSurf.com |